Receive Our Newsletter

Genentech Announces Interim Results from Phase III HAVEN 2 Study


On April 16, 2017 Genentech announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A and inhibitors to factor VIII. According to this Genentech’s press releases, “interim analysis after a median of 12 weeks of treatment, emicizumab prophylaxis showed a clinically meaningful reduction in the number of bleeds over time.”

Read Genentech’s full press release regarding this data in it’s entirety.

Comments (No comments)

Assisting and Advocating for the Bleeding Disorders Community